SurModics IVD to Present at Biomarker World Congress in Philadelphia, PA

May 14, 2012 at 8:01 AM EDT

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--May. 14, 2012-- SurModics IVD Inc., a wholly owned subsidiary of SurModics, Inc. (NASDAQ:SRDX) and a market leader for immunoassay reagents for diagnostic tests, is pleased to announce it will present a poster entitled “Evaluation of Immunoassay Interference Reduction Technologies” at Biomarker World Congress in Philadelphia, PA from May 21 – 23, 2012.

The poster and representatives of SurModics will present products that mitigate non-specific binding and interferences in immunoassays. These products provide useful tools to develop and optimize immunoassays that are sensitive, reproducible and robust, while demonstrating the ability to reduce assay interference across multiple applications.

To learn more about SurModics'in vitro diagnostic products, please visit our website (, or contact customer service at 952-500-7200 or Easy online ordering is available at SurModics is a registered trademark of SurModics, Inc.

About SurModics, Inc.
SurModics' mission is to exceed our customers' expectations and enhance the well-being of patients by providing the world's foremost, innovative surface modification technologies and in vitro diagnostic chemical components. The Company partners with the world's leading and emerging medical device, diagnostic and life science companies to develop and commercialize innovative products designed to improve patient diagnosis and treatment. Core offerings include surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for in vitro diagnostic test kits and microarrays. SurModics is headquartered in Eden Prairie, Minnesota. For more information about the Company, visit The content of SurModics' website is not part of this release or part of any filings the Company makes with the SEC.

Source: SurModics, Inc.

SurModics, Inc.
Tim Arens, 952-500-7000
Vice President Finance and interim Chief Financial Officer